Latest Insider Transactions at Bicycle Therapeutics PLC (BCYC)
This section provides a real-time view of insider transactions for Bicycle Therapeutics PLC (BCYC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BICYCLE THERAPEUTICS plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BICYCLE THERAPEUTICS plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2023
|
Nigel Crockett CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+35.0%
|
-
|
|
Jan 03
2023
|
Gregory Paul Winter |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+3.19%
|
-
|
|
Jan 03
2023
|
Janice Bourque |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+34.85%
|
-
|
|
Jan 03
2023
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
1,815
-5.58%
|
$52,635
$29.06 P/Share
|
|
Jan 03
2023
|
Lee Kalowski President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+35.0%
|
-
|
|
Jan 03
2023
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,817
-4.43%
|
$52,693
$29.06 P/Share
|
|
Jan 03
2023
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+29.93%
|
-
|
|
Jan 03
2023
|
Michael Skynner CHIEF TECHNOLOGY OFFICER |
SELL
Open market or private sale
|
Direct |
1,801
-2.45%
|
$52,229
$29.06 P/Share
|
|
Jan 03
2023
|
Michael Skynner CHIEF TECHNOLOGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+19.2%
|
-
|
|
Jan 03
2023
|
Dominic Smethurst Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,801
-4.68%
|
$52,229
$29.06 P/Share
|
|
Jan 03
2023
|
Dominic Smethurst Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+31.25%
|
-
|
|
Jan 03
2023
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+34.85%
|
-
|
|
Jan 03
2023
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-1.8%
|
$174,000
$29.06 P/Share
|
|
Jan 03
2023
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
57,500
+14.74%
|
-
|
|
Jan 03
2023
|
Jose Carlos Gutierrez Ramos |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+34.85%
|
-
|
|
Jan 03
2023
|
Richard N Kender |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+34.85%
|
-
|
|
Mar 25
2022
|
Alistair Milnes CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,155
+18.65%
|
$103,100
$20.12 P/Share
|
|
Jan 03
2022
|
Alistair Milnes CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 03
2022
|
Janice Bourque |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 03
2022
|
Nigel Crockett CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 03
2022
|
Jose Carlos Gutierrez Ramos |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 03
2022
|
Lee Kalowski President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Jan 03
2022
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+38.98%
|
-
|
|
Jan 03
2022
|
Richard N Kender |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 03
2022
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+15.38%
|
-
|
|
Jan 03
2022
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jan 03
2022
|
Michael Skynner CHIEF TECHNOLOGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+21.09%
|
-
|
|
Jan 03
2022
|
Dominic Smethurst Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+41.67%
|
-
|
|
Jan 03
2022
|
Gregory Paul Winter |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+2.87%
|
-
|
|
Jan 03
2022
|
Veronica Gh Jordan Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Dec 22
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
97,860
-100.0%
|
$5,675,880
$58.01 P/Share
|
|
Dec 22
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
97,860
+50.0%
|
$782,880
$8.48 P/Share
|
|
Dec 21
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,477
+50.0%
|
$216,678
$14.0 P/Share
|
|
Dec 21
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
44,537
-100.0%
|
$2,538,609
$57.11 P/Share
|
|
Dec 21
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
44,537
+50.0%
|
$356,296
$8.44 P/Share
|
|
Dec 20
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
7,603
-100.0%
|
$433,371
$57.02 P/Share
|
|
Dec 20
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
7,603
+50.0%
|
$60,824
$8.41 P/Share
|
|
Oct 18
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
49
-0.02%
|
$2,940
$60.0 P/Share
|
|
Oct 15
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
320
-0.14%
|
$19,200
$60.05 P/Share
|
|
Oct 14
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,631
-2.01%
|
$277,860
$60.0 P/Share
|
|
Oct 11
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-1.07%
|
$270,000
$54.22 P/Share
|
|
Oct 05
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,178
-100.0%
|
$98,010
$45.1 P/Share
|
|
Oct 01
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,188
-35.29%
|
$53,460
$45.0 P/Share
|
|
Sep 23
2021
|
Dominic Smethurst Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$108,000
$18.55 P/Share
|
|
Sep 16
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,955
-36.74%
|
$87,975
$45.01 P/Share
|
|
Sep 15
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-36.05%
|
$135,000
$45.0 P/Share
|
|
Sep 02
2021
|
Nicholas Keen CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-54.58%
|
$400,000
$40.0 P/Share
|
|
Sep 02
2021
|
Lee Kalowski President and CFO |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$400,000
$40.0 P/Share
|
|
Sep 02
2021
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$90,000
$9.82 P/Share
|
|
Sep 02
2021
|
Kevin Lee CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-2.08%
|
$200,000
$40.0 P/Share
|